Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
116 studies found for:    Open Studies | "Amyloidosis"
Show Display Options
Rank Status Study
21 Recruiting Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Condition: Relapsed or Refractory Systemic Light Chain Amyloidosis
Interventions: Drug: IXAZOMIB;   Drug: Dexamethasone;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Thalidomide;   Drug: Lenalidomide
22 Recruiting Body Composition in Systemic Amyloidosis
Condition: Amyloidosis
Intervention: Other: Dietary advice
23 Recruiting Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Daratumumab
24 Not yet recruiting Prevalence of Amyloidosis and Carpal Tunnel
Condition: Amyloid Neuropathy, Carpal Tunnel
25 Recruiting Molecular Imaging of Primary Amyloid Cardiomyopathy
Conditions: Amyloidosis, Primary;   Cardiomyopathy
Interventions: Radiation: F-18 florbetapir/C-11 acetate PET;   Device: MRI
26 Not yet recruiting Daratumumab for the Treatment of Patients With AL Amyloidosis
Condition: AL Amyloidosis
Intervention: Drug: daratumumab
27 Recruiting Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Conditions: Plasma Cell Dyscrasias;   Monoclonal Gammopathy of Undetermined Significance;   AL Amyloidosis;   Multiple Myeloma
Intervention: Procedure: tissue banking
28 Recruiting Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Conditions: Multiple Myeloma;   Amyloidosis
Interventions: Device: Melphalan;   Drug: Pegfilgrastim;   Procedure: Autologous Hematopoietic Progenitor Cell Transplant
29 Recruiting First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Conditions: Light Chain Deposition Disease;   Primary Systemic Amyloidosis
Interventions: Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone;   Other: Laboratory Biomarker Analysis
30 Recruiting The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis
Condition: Primary Systemic (AL) Amyloidosis
Interventions: Drug: NEOD001;   Other: Placebo
31 Recruiting Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
Condition: Amyloidosis
Intervention: Drug: Bortezomib
32 Not yet recruiting Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy
Conditions: Cerebral Amyloid Angiopathy;   Intracerebral Hemorrhage
33 Recruiting Amyloïd Load in Elderly Population: Effect of Cognitive Reserve
Conditions: Plaque, Amyloid;   Cognitive Deficits
Interventions: Other: PET;   Other: MRI;   Other: neuropsychological tests
34 Recruiting Escitalopram Effects on CSF Amyloid Beta
Condition: Amyloid Beta Protein
Intervention: Drug: Escitalopram or Placebo
35 Recruiting Biomarker for Patients With Transthyretin-Related Familial Amyloidotic Polyneuropathy
Conditions: Metabolic Diseases;   Amyloid Neuropathies;   Amyloidosis, Familial;   Polyneuropathies
36 Not yet recruiting Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis
Conditions: Amyloid Cerebral Angiopathy;   Alzheimer Disease
Interventions: Device: Pet scan with FBB;   Device: MRI scan;   Biological: APO E genotyping
37 Recruiting Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction
Condition: Amyloid-beta
Interventions: Drug: Sodium Oxybate;   Behavioral: Sleep deprivation
38 Recruiting 18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study
Condition: Amyloid PET Imaging
Intervention: Device: 18F-Florbetaben PET
39 Recruiting A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects
Condition: Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
Interventions: Drug: ALN-TTRSC02;   Drug: Sterile Normal Saline (0.9% NaCl)
40 Not yet recruiting Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level
Condition: Observational

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years